期刊文献+

不同严重度COPD患者血清MMP-9、TIMP-1浓度变化及相关性研究 被引量:5

Concentration changes of serum MMP-9 and TIMP-1 and their relativity with different disease severities in COPD patients
下载PDF
导出
摘要 目的:探讨不同严重度慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者血清MMP-9、TIMP-1的浓度变化及相关性。方法:用酶联免疫吸附法(ELISA)测定53例不同病情分度的COPD患者(轻度11例、中度16例、重度14例、极重度12例)血清MMP-9、TIMP-1的浓度(ng/ml)。结果:与轻度(52.46±10.59;161.63±7.26)COPD患者相比,中度(111.73±25.40;201.73±19.27)、重度(188.41±20.72;257.05±13.97)、极重度(236.31±10.93;313.07±15.97)患者血清MMP-9、TIMP-1浓度显著升高。与中度COPD患者相比,重度、极重度患者血清MMP-9、TIMP-1浓度显著升高;与重度COPD患者相比,极重度患者血清MMP-9、TIMP-1浓度显著升高,P均<0.05;不同COPD病情严重度与MMP-9、TIMP-1、MMP-9/TIMP-1均呈正相关,相关系数分别为0.791,0.782,0.766,P<0.01。结论:随着COPD患者病情严重程度的加重,血清MMP-9、TIMP-1的浓度及MMP-9/MMP-1比率升高,并且与气流阻塞(用FEV1/FVC%及FEV1%预计值表示)成负相关,可以作为评价患者病情严重程度的指标,也可初步预测治疗效果。 Objective:To estimate the serum concentration of matrix metalloproteinase-9(MMP-9),tissue inhibitors of matrix metalloproteinase(TIMP-1) in the patients with chronic obstructive pulmonary disease(COPD) and to evaluate the correlation between MMP-9 and TIMP-1 with the disease severity in COPD.Methods:Fifity-three COPD patients were enrolled(mild 11,moderate 16,severe 14,extreme severe 12).In four groups the spirometry was performed and the serum concentrations were measured using enzyme-linked immunosorbent assay(ELISA).Results:Moderate,severe and extreme severe COPD patients had increased serum MMP-9 and TIMP-1 levels compared with mild COPD patients.Furthermore,severe and extreme severe COPD patients had increased serum MMP-9 and TIMP-1 levels compared with moderate COPD patients.The extreme severe COPD patients had significantly increased serum MMP-9 and TIMP-1 levels than severe COPD(all P0.05).The different disease severities of COPD all were positively correlated with serum MMP-9 and TIMP-1 levels and MMP-9/ TIMP-1.The related coefficients were 0.791,0.782 and 0.766 respectively(P0.01).Conclusion:With the aggravation of severities in COPD,serum MMP-9 and TIMP-1 levels and MMP-9/TIMP-1 ratio all are increased and negatively correlated with airflow obstruction(FEV1/FVC% and FEV% predicted value),which might be used as the indexes for evaluating the disease severity and preliminarily predicting the curative effects.
出处 《现代医药卫生》 2011年第9期1289-1290,共2页 Journal of Modern Medicine & Health
  • 相关文献

参考文献8

  • 1Culpitt SV,Rogers DF,Traves SL,et al. Sputum matrix metalloproteases comparison between chronic obstructive pulmonary disease and asthma[J].Respir Med, 2005,99(6) : 703.
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 3Oikonomidi S, Kostikas K, Tsilioni I, et al. Matrix metalloproteinases in respiratory disease:frompathogenesis to potential clinical implica- tions[J].Curr Med Chem, 2009,16(10): 1214.
  • 4Merce PF,Shute JK,Bhowmik A,et al. MMP-9,TIMP-1 and inflam- matory ceils in sputum from COPD patients during exacerbation[J]. Respir Res, 2005,6(5) :465.
  • 5Brajer B, Batura-Gabryel H, Nowicka A,et al. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression[J].J Physiol Pharmaco1,2008,59(6):145.
  • 6孔英君,孙文学,张一梅,石玉枝.慢性阻塞性肺疾病患者基质金属蛋白酶9/金属蛋白抑制1的比率与气流阻塞关系的研究[J].中国现代医学杂志,2008,18(6):747-750. 被引量:8
  • 7Higashimoto Y, Yamagata Y, Iwat T, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients[J]. Eur Respir, 2005,25 : 885.
  • 8Foronjy R, Nkyimbeng T, Wallace A,et al. Transgenic expression of matrix metalloproteinase-9 cause adult-onset emphysema in mice associated with the loss of alveolar elastin[J].Am J Physiol Lung Cell Mol Physiol,2008,294(6) : 1149.

二级参考文献24

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2侯冬青,杨辉红,李新红.老年慢性阻塞性肺病患者医院肺炎病原菌及耐药性分析[J].中国现代医学杂志,2006,16(7):1083-1085. 被引量:10
  • 3GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
  • 4Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
  • 5Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
  • 6冉丕鑫 王辰 姚婉贞 等.我国部分地区慢性阻塞性肺疾病流行病学研究[J].中华结核和呼吸杂志,2007,.
  • 7HOGG JC, SENIOR RM. Chronic obstructive pulmonary disease-part 2: pathology and biochemistry of emphysema [J]. Thorax, 2002, 57: 830.
  • 8HIGASHIMOTO Y, YAMAGATA Y, IWATA T, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients[J]. Eur Respir J, 2005, 25: 885-890.
  • 9HOGG JC, CHU F, UTOKAPARCH S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease [J]. N Engl J Med, 2004, 350: 2645-2653.
  • 10RETAMALES I, WM ELLIOTT, B MESHI, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection[J]. Am J Respir Crit Care Med, 2001, 164: 469-473.

共引文献8241

同被引文献68

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部